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GENERATION OF HEMOPHILIA B MODEL HEPATOCYTE? DERIVED 
 
 FROM HUMAN IPSC VIA CRISPR/CAS9 MEDIATED GENOME EDITING 
 
 
PETER KWAK 
ABSTRACT 
 Permanent repair of the F9 gene is a significant goal to cure Hemophilia B 
disease. Advanced gene therapy using CRISPR/Cas9 system can increase circulation 
level of Factor IX proteins to a significant level without the need of demanding infusions 
of FIX concentrates. Induced pluripotent stem cells represent an ideal cell for gene 
therapy because patient-derived cells could be reprogrammed into iPSCs, genetically 
modified, selected, expanded and then induced to differentiate into fully functional 
hepatocytes in vitro. This study covered a portion of a 5-year project which ultimately 
aims at establishing therapeutic results in transgenic Hemophilia B mice by injecting 
genetically corrected iPSC-derived hepatocytes into the liver. The purpose of this thesis 
is to summarize what has been completed up to now: generation of the proper model of 
Hemophilia B human iPSCs using CRISPR/Cas9-mediated genome editing and 
differentiation of healthy and disease specific iPSCs into hepatocytes which will allow 
disease modelling to look for cell function, viability, homogeneity and drug screening. 
Further research will be done to effectively knock-in the F9 allele into liver safe harbor 
site of disease specific iPSCs, which will express FIX at a significant level to show 
therapeutic effects.  
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INTRODUCTION 
Hemophilia B (HB) is a congenital bleeding disorder caused by a mutation in the 
X chromosome gene encoding coagulation factor IX (FIX). Defect in this protein, which 
is one of the serine protease involved in the blood clotting cascade, results in severe 
bleeding episodes (e.g., joint and muscle bleeding, purpura, and intracranial hemorrhage). 
Most common feature of HB is recurrent spontaneous hemarthrosis, a bleeding into joint 
spaces. This symptom is present in severe (factor IX plasma procoagulant level, <1% of 
the normal value) or moderate cases (<5% of the normal value) and rarely in mild cases, 
(5 to 40% of the normal value) (Mannucci & Tuddenham, 2001). Approximately 60% of 
HB patients are severe cases, who may have several critical spontaneous bleeding 
episodes every year. Several studies reported a dramatically shortened life-expectancy of 
hemophilia patients from 16 to 23 years. However, since the introduction of prophylactic 
therapy and continual improvement in extending the half-life of coagulation factor 
concentrates, these patients can live a normal life if a diagnosis and treatment are started 
early. It is reported that therapeutics levels can be obtained with infusions of exogenous 
FIX every 2 weeks (Santagostino et al., 2012). 
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Figure 1 Hemophilia B - current to future therapy Current treatment for HB is infusion of exogenous coagulation 
factor protein every 2 weeks. There was continual improvement in increasing the half-life of FIX in circulation, 
however this is still a big burden for hemophilia patients. In order to achieve permanent repair of F9 gene and produce 
endogenous FIX, gene correction is the next way forward.  
 
Current Status: Cost, Consistency and Inhibitors  
 Since the half-life of FIX is approximately 24 hours, HB patients need continuous 
lifelong infusions of FIX concentrates since early childhood. Although such prophylactic 
therapy significantly improved the quality of life, it did not eliminate bleeding episodes 
altogether. Since exogenous factor replacement requires regular infusions, there are peaks 
and troughs of FIX activity between infusions and require careful planning of daily lives. 
Also, patients’ immune system can develop allo-antibodies, known as inhibitors, that can 
neutralize the effect of exogenous FIX.   
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Because of such demanding infusions and high costs of prophylactic therapy, 
permanent repair of the F9 gene is a significant goal to cure HB.  
 
Endogenous Expression of F9 Using Gene Therapy 
HB patients can reach homeostasis as long as the level of functional FIX increases 
to at least 1% of normal value (Wang et al. 1999). Thus, gene therapy could address 
many of the limitations of current therapies while continuously producing small 
quantities of endogenous FIX. However, early clinical gene supplementation that started 
in the late 1990s could not overcome the limitation of sustained production of FIX (Kay 
et al., 2000; Powell et al., 2003; Roth et al., 2001). Advancement in gene therapy where 
adeno-associated virus (AAV) vectors mediate transduction to introduce F9 cDNA into 
the liver, muscle or fibroblast cells increased plasma FIX concentration (Chen et al., 
2003; Jiang et al., 2006; Kay et al., 1993; Lu et al., 1993; Manno et al., 2003; Manno et 
al., 2006; Nathwani et al., 2014). Current studies aim to randomly or site-specifically 
insert F9 gene into the genome using transposon or gene editing system (zinc finger 
nucleases, ZFN) (Anguela et al., 2013; H. Li et al., 2011; Sharma et al., 2015; Yant et al., 
2000). All these treatments showed improvement in FIX secretion and decreased 
bleeding episodes. Several design variations improved the expression and duration of 
FIX. Notably, FIX expression was sustained for more than 8 weeks when F9 gene was 
site specifically directed to Alb gene using AAV vector and ZFN to share the promotor of 
highly expressive Alb gene  (Sharma et al., 2015). Another complication from using AAV 
vector was the risk of an immune response against AAV-transduced hepatocytes. 
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Because of such rejection from the immune system, previous AAV-mediated gene 
transfer studies needed enhancement in terms of increasing the duration of FIX 
circulation (Manno et al., 2006) or increasing the expression levels (Nathwani et al., 
2014). In order to minimize the vector dose dependent immune response, there needed to 
be a way to show therapeutic benefit while injecting the lowest dose of AAV vector. 
Most recent study (George et al., 2017) aimed to solve this problem by using an AAV 
vector containing a hyperfunctional factor IX variant gene (Padua) that targets the liver. 
This high-activity factor IX variant, R338L, is a gain-of-function mutation in the factor 
IX catalytic domain and expresses factor IX as much as 12 times than that of wildtype F9 
gene (Crudele et al., 2015; Simioni et al., 2009). All 10 patients who participated in this 
study had sustained mean circulation level of FIX of 33.7 ± 18.5%. Participants no longer 
needed prophylaxis therapy with FIX concentrates and bleeding rates were decreased to 
zero, indicating that factor IX levels were sustained at levels above 5 IU per deciliter 
(George et al., 2017).  
More in detail, an Editorial on New England Journal of Medicine was published 
on December 10th 2017 with a hopeful sentiment that “A Cure for Hemophilia [is] within 
Reach” (van den Berg, 2017), citing several recent studies including the research by 
George and colleagues mentioned above (George et al., 2017). Although these clinical 
results seem promising, there needs to be an explanation for the large variation among 
patients in order to optimize dosage level for each patient. In addition, most hemophilia 
patients were excluded from the study pool because they were AAV positive, inhibitor-
positive or had active hepatitis. Although the dosage of AAV vector was significantly 
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reduced, it is still necessary to point out the risk of insertional oncogenesis from random 
integration of donor DNA when using AAV and especially lentivirus gene therapy. 
Several other methods are currently being developed including hematopoietic stem cells 
as a target for hemophilia gene therapy. These stem cells could differentiate into platelets, 
directly delivering coagulation factors into the circulation (VandenDriessche & Chuah, 
2017). Gene editing technologies using ZFN or clustered regularly interspaced short 
palindromic repeats/CRISPR-associated nuclease 9 (CRISPR/Cas9) could open up new 
perspectives for gene correction (Valdmanis & Kay, 2017).  
 
CRISPR/Cas9 Mediated Gene Therapy 
Gene correction is an ideal solution for genetic disorders as the mutation in the 
DNA can be permanently corrected. When an exogenous donor DNA template with the 
correct sequence is presented into the target cell nucleus or genome, it replaces the 
mutation site by homology-directed repair (HDR). Because the spontaneous HDR occurs 
very rarely as 1 × 10-6, programmable nucleases that specifically targets the mutation site 
is needed to increase this rate (Iiizumi et al., 2008).  Recently, a RNA-guided 
programmable nuclease, called CRISPR/Cas9 provided several advantages over previous 
programmable nucleases. CRISPR/Cas9 is adapted from microbial adaptive immune 
mechanism (Figure 2A) (Jinek et al., 2012) and was first applied in mammalian cells in 
2013 (Cong et al., 2013; Mali et al., 2013). There are two components in CRISPR/Cas9 
system, which are an endonuclease Cas9 and a single guide RNA (sgRNA) (Figure 2B). 
Cas9 nuclease contains two catalytic domains RuvC and HNH (Doudna & Charpentier, 
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2014). When a protospacer-adjacent motif (PAM) sequence is present on the opposite 
strand, sgRNA guides Cas9 protein to the target site by base-pairing and Cas9 
endonuclease induces double strand breaks (DSBs). Subsequently, cells spontaneously 
promote two DNA repair pathways. HDR occurs if the homologous sequence from the 
donor template is available and leads to site-specific gene correction. Otherwise, non-
homologous end joining (NHEH) occurs, which are very error prone and thus leads to 
small insertion or deletion (indel), resulting in frameshift mutation and a gene knock-out 
(Figure 2C) (Cong et al., 2013; Doudna & Charpentier, 2014; Mali et al., 2013). 
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Figure 2. Components of CRISPR/Cas9 and its mechanisms in gene editing (A) Schematic representation of 
CRISPR locus from Streptococcus pyogenes (B) Nuclease Cas9 protein is directed to target sequence by a single guide 
RNA (sgRNA) in the presence of a PAM sequence on the opposite strand. (C) Double-strand breaks are generated by 
nuclease Cas9, leading to either homologous directed repair (HDR) or non-homologous end-joining (NHEJ). HDR 
precisely corrects or replaces the existing gene sequence whereas NHEJ leads to small insertion or deletion (indel), 
leading to premature stop codon and a gene knock-out. tracrRNA, trans-activating crRNA; crRNA, CRISPR RNA; 
PAM, protospacer-adjacent motif, HA, homologous arm; DS, donor sequence; DSD, double-strand DNA donor; 
ssODN, single-stranded oligonucleotide DNA ((Xiao-Jie, Hui-Ying, Zun-Ping, Jin-Lian, & Li-Juan, 2015). 
Because CRISPR/Cas9 system is an RNA-guided gene editing tool, it only requires the 
design of sgRNA to target a new for gene correction, which means that the same Cas9 
nuclease can be used in all cases. Compared with ZFN or TALEN, which require de novo 
synthesis of the whole guide protein, CRISPR/Cas9 system offers highly specific and 
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efficient gene editing while operating at a significantly reduced cost. Therefore, this 
technology opened up a new generation of gene engineering with wide applications in 
cell lines including induced pluripotent stem cells (iPSC) from patients (Schwank et al., 
2013; Xu et al., 2015; Dever et al., 2016).   
 
iPSC-Derived Hepatocytes Suitable for HB Gene Therapy 
FIX is produced in the liver hepatocytes, but there are several reasons why it is 
not feasible to show therapeutic effects by directly manipulating genes in hepatocytes. It 
is generally difficult to manage them as they are highly susceptible to freezing and 
thawing damage. It is also impossible to expand hepatocyte as they can divide only once 
or twice in vitro, in the presence of Hepatocyte Growth Factor (Terry, Dhawan, Mitry, 
Lehec, & Hughes, 2010). There is also immunogenicity to consider when using allogenic 
hepatocytes. Transplanted cells are not fully functional because of immunosuppressive 
drugs and a cell-mediated immune response, often leading apoptosis and cell loss 
(Najimi, Smets, & Sokal, 2009). In order to use autologous hepatocytes, a lobectomy is 
necessary, requiring about 20% of the liver for hepatocyte isolation, which is not feasible 
with HB patients. Most importantly, HDR, which is necessary for gene correction, has a 
lower frequency of occurrence in post-mitotic cells, such as myocytes and hepatocytes 
(Hsu, Lander, & Zhang, 2014). All these limitations prevented the advancement of ex 
vivo therapeutic application for HB and directed the research focus to in vivo studies 
using AAV vectors. 
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 The recent discovery that adult somatic cells can be reprogrammed back to cells 
with similar characteristics to human embryonic stem cells boosted hopes for 
regenerative medicine. These cells, called iPSC, can be generated by expression of four 
transcription factors and have the capacity for self-renewal and differentiation into any of 
the three primary germ layers: the endoderm, mesoderm and ectoderm (Park et al., 2008; 
Takahashi et al., 2007). Therefore, once the conditions required to induce differentiation 
of iPSC into hepatocyte have been determined, patient-specific hepatocytes can be 
produced in large quantity (Figure 3) (Maehr et al., 2009; Soldner et al., 2009).   
 
Figure 3. hiPSC-derived hepatocytes from patients’ somatic cells (Hannoun, Steichen, Dianat, Weber, & Dubart-
Kupperschmitt, 2016). 
Ultimately, iPSC represents an ideal cell for gene therapy because patient-derived cells 
could be reprogrammed into iPSCs, genetically corrected, selected one by one, expanded 
to yield large clonal populations and then differentiated into fully functional hepatocytes 
in vitro. These patient-specific iPSCs could then be used for therapeutic autologous 
transplantation. Because these cells are unique to the patient concerned, these cells would 
provide the best possible functional result, as they are in their natural habitat, without 
eliciting immune response and eliminating the problems arising from the use of 
immunosuppressive regimens (Zhang et al., 2011). There have been several studies using 
CRISPR/Cas9 to genetically edit patient-derived iPSCs of congenital diseases, including 
β-thalassemia (Xie et al., 2014) and Duchenne muscular dystrophy (H. L. Li et al., 2015). 
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SPECIFIC AIMS 
 Currently, there are no iPSCs modeling HB disease. The purpose of this study is 
to generate the proper model of human HB hepatocytes using CRISPR/Cas9-mediated 
genome editing on healthy human iPSCs. Differentiation of healthy iPSCs into 
hepatocytes can be used for developing bioengineered liver, allogenic cell therapy, or 
drug screening.  Differentiation of disease specific iPSCs, which is genetically modified 
to model HB, into hepatocytes will allow disease modelling to look for cell function, 
viability and homogeneity as well as drug screening. 
 It is crucial to outline the entire project and give the perspective of where this 
particular study fits in. The entire project is designed for a 5-year term with four 
institutions participating (represented by different colors in Figure 4). Each organization 
is specialized and responsible for a specific aspect of the study (Figure 4). The goal of the 
study is to develop a method of permanent gene therapy for HB patients. 
Toolgen Inc. (red) is managing the entire project and is responsible for creating 
DNA donor template and designing sgRNAs that will specifically target the site of 
interest, essentially designing the entire CRISPR/Cas9 System. The project will examine 
two different methods for final therapeutic evaluations, ex vivo and in vivo.  
Gachon University School of Medicine (blue), where the research was done for 
this particular thesis, is responsible for ex vivo study, manipulating iPSCs to genetically 
knock-out F9 gene from healthy iPSCs to create HB model (topic of this thesis) and then 
knocking-in F9 gene into the liver safe harbor site (Figure 5). The liver safe harbor site 
will be a highly expressed locus in hepatocytes, so that even a small frequency of 
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successful knock-in (0.01-0.05%) to this site can induce an expression of FIX to a 
significant level of therapeutic effects. Two iPSC lines, F9 knock-out (control) and F9 
knock-in (experiment), will be differentiated into hepatocytes to be injected into 
transgenic mouse model for HB.   
Yonsei University will look into in-vivo study (purple), testing different AAV 
serotypes to determine which will most effectively deliver the vectors into the liver. After 
production of virus capsid, AAV vectors will be tested in primary hepatocytes in vitro to 
develop proof-of-concept (POC). 
Seoul National University (green) will develop transgenic knock-out mice that 
model HB disease using CRISPR/Cas9. Two different therapeutic methods, ex vivo and 
in vivo, will be tested in these transgenic mice to determine which method is more safe 
and effective in increasing FIX expression. In ex vivo method, hepatocytes derived from 
genetically modified iPSCs will be injected into the liver. In in vivo study, AAV vector 
will induce gene transfer in these transgenic mice, directly manipulating hepatocytes.  
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Figure 4 Overall outline of HB project with Toolgen, Inc. Two methods, ex vivo (blue) and in vivo (purple), will be 
tested and verified for the best therapeutic outcomes in transgenic mouse model of HB. This thesis is based on the 
specific portion of the study, generating F9 knock-out iPSC differentiated into hepatocytes (highlighted),      
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Figure 5 F9 Knock-in to liver safe harbor site via CRISPR/Cas9 genome editing sgRNAs will be designed to target 
specific liver site where expression level is very high. Even a small percentage of knock-in efficiency into liver safe 
harbor site will enable a continual production of coagulation factor IX to a level  of significant therapeutic effect. 
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METHODS 
 
iPS Cell Culture 
Human induced pluripotent stem cells (hiPSCs) were obtained from Korean 
National Institute of Health. This cell line, hFmiPS1, was routinely maintained on 
mitomycin C inactivated mouse embryonic fibroblast (MEF) feeder cells and cultured 
with human embryonic stem cell medium which contains DMEM/F12 (Gibco, Waltham, 
MA), 20% knockout serum replacement (Gibco, Waltham, MA), 1% non-essential amino 
acids (Gibco, Waltham, MA), 100µM mercaptoethanol (Invitrogen, Carlsbad, CA) and 
10ng/ml bFGF (R&D systems, Minneapolis, MN). Conventionally cultured iPSCs were 
mechanically dissociated into small clumps and transferred to matrigel (BD Biosciences, 
Franklin Lakes, NJ) coated 60mm dish which contained 4 mL mTeSR-E8 (STEMCELL 
Technologies, Vancouver, BC) iPSC maintenance medium supplemented with 4 µl 
ROCK inhibitor (1:1000) (STEMCELL Technologies, Vancouver, BC). Cell culture was 
maintained in a humidified incubator set at 37°C and 5% CO2.  The media was changed 
daily and the cells were sub-cultured every 5 days. 
Table 1 Information about iPS cell line, hFmiPS1 
Cell Line Parental Cell Passage 
Number 
Depository Authority Cryopreservation 
Date 
hFmiPS1 Human Dermal 
Fibroblast 
26 Korean National 
Institute of Health 
2014.07.10 
 
 
Recombinant Cas9 Protein and sgRNA Targeting F9 
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 50 µg of lyophilized Cas9 Wild-Type protein was obtained from Toolgen Inc (Cat 
No# TGEN_CP1, Seoul, South Korea). Customized sgRNA targeting F9 allele was also 
obtained from Toolgen Inc, Seoul, South Korea. Lyophilized Cas9 protein was 
reconstituted to the final concentration of 10µg/mL by mixing with glycerol 
reconstitution buffer.  
 
Transfection to Induce F9 Knock-Out  
15µg of Cas9 protein was mixed with 20µg of sgRNA, which corresponded to 1.5 
µl of Cas9 protein with 2.5 µl of sgRNA with a concentration of 8µg/µl. Mixture was 
incubated at RT for 10 minutes. 100µl of Single Nucleocuvette®  (Lonza) was prepared 
with 82 µl of Nucleofector®  Solution (Lonza) and 18 µl of Supplement (Lonza). iPSCs 
were harvested using ACCUTASE™ (STEMCELL Technologies, Vancouver, BC) and 
counted to prepare 2 x 105 cells in 15 mL conical tube. Cells were centrifuged at 300 x g 
for five minutes at room temperature (RT) and supernatant was removed. 100µl of Single 
Nucleocuvette®  solution (Lonza, Basel, Switzerland) was added to resuspend the cells 
and 4 µl of prepared complex of CRISPR/Cas9 system was added to prepare the 
mastermix, which was transferred into the Nucleocuvette®  Vessels (Lonza, Basel, 
Switzerland). Transfection was carried out with Amaxa®  4D-Nucleofector®  (Lonza, 
Basel, Switzerland) using the code number H9 for human embryonic cells. After 
transfection was complete, Nucleocuvette®  Vessel was removed from the retainer and 
cells were resuspended with 2mL of pre-warmed mTeSR-E8 (STEMCELL Technologies, 
Vancouver, BC) iPSC maintenance medium supplemented with 2 µl ROCK inhibitor 
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(1:1000) (STEMCELL Technologies, Vancouver, BC). Cells were then seeded in a 
matrigel (BD Biosciences, Franklin Lakes, NJ) coated 6-well plate and placed in the 
incubator at 37°C ± 1°C, 5% CO2, and >90% humidity.  
 
F9 Primer Design 
 sgRNA to knock-out F9 allele was designed to target specific sequence 
containing PAM. Using this target site, the full sequence of F9 was found in 
BLAST/BLAT search. Full sequence of F9 was added to the input box in Primer3Plus. 
Target region was selected with the setting of product size ranging from 600 to 700 base 
pairs. Primer was selected so that when the double strand break occurs with the use of 
CRISPR/Cas9 system, one product will have a size around 100 base pairs and another of 
620 base pairs, easily differentiated by gel electrophoresis.  
Table 2 Primer sequence for F9 allele. Target site is indicated by bold. Forward and reverse primer sequences are 
underlined. 
CAAAGACCCATTGAGGGAGATGGACATTATTTCCCAGAAGTAAATACAGCTCAGCTTGTAC
TTTGGTACAACTAATCGACCTTACCACTTTCACAATCTGCTAGCAAAGGTTATGCAGCGCG
TGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACT
CAGTGCTGAATGTACAGGTTTGTTTCCTTTTTTAAAATACATTGAGTATGCTTGCCTTTTAGA
TATAGAAATATCTGATGCTGTCTTCTTCACTAAATTTTGATTACATGATTTGACAGCAATAT
TGAAGAGTCTAACAGCCAGCACGCAGGTTGGTAAGTACTGGTTCTTTGTTAGCTAGGTTTTC
TTCTTCTTCATTTTTAAAACTAAATAGATCGACAATGCTTATGATGCATTTATGTTTAATAAA
CACTGTTCAGTTCATGATTTGGTCATGTAATTCCTGTTAGAAAACATTCATCTCCTTGGTTTA
AAAAAATTAAAAGTGGGAAAACAAAGAAATAGCAGAATATAGTGAAAAAAAATAACCAC
ATTATTTTTGTTTGGACTTACCACTTTGAAATCAAAATGGGAAACAAAAGCACAAACAATG
GCCT 
 
 
Genomic DNA Extraction 
DNA was extracted from control and transfected cells using TIANamp Genomic 
DNA Kit (TIANGEN, Beijing, China). Cell lysate was prepared for each sample and 20 
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µl of Proteinase K was added and mixed thoroughly by vortex. 200 µl of Buffer GB was 
added to the sample, mixed and incubated at 70°C for 10 minutes. 200 µl of ethanol 
(100%) was added to the sample, mixed by vortex. Mixture was transferred into the Spin 
Column CB3 and centrifuged at 12,000rpm for 30 s. Flow-through was discarded and the 
spin column was placed into the collection tube. 500 µl of Buffer GD was added to Spin 
Column CBs and centrifuged at 12,000 rpm for 30 s. Flow-through was discarded and the 
spin column was placed into the collection tube. 600 µl of Buffer PW was added to the 
Spin Column CB3 and centrifuged at 12,000 rpm for 30 s. Flow-through was discarded 
and spin column was placed into the collection tube. Previous step was repeated and the 
spin column with the collection tube was centrifuged at 12,000 rpm for 2 minutes to 
completely dry the membrane. The Spin Column CB3 was now placed in a clean 1.5 ml 
microcentrifuge tube, and 100 µl of Buffer TE was directly pipetted to the center of the 
membrane, incubated at RT for 3 minutes and then centrifuged for 2 minutes at 12,000 
rpm.  
 
Targeted Deep Sequencing 
 Genomic DNA from two samples (control and transfected) were passed onto 
Toolgen Inc. for deep sequencing analysis. Genomic DNA segments spanning the on-
target sites were amplified using Phusion polymerase (New England BioLabs, Ipswich, 
MA). The resulting PCR amplicons were subjected to paired-end sequencing using 
Illumina MiSeq.  
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The Cellartis DEF-CS Culture System 
 The human iPS Cell line, hFmiPS1 (Korean National Institute of Health), was 
differentiated to hepatocytes using Cellartis®  iPS Cell to Hepatocyte Differentiation 
System (Takara Bio, Kusatsu, Japan) (Figure 6). The entire differentiation process took 
about three weeks to complete after hiPSC were adapted to Cellartis DEF-CS Culture 
System (Takara Bio, Kusatsu, Japan) (Table 3). All reagents required for differentiation 
system are outlined in Table 4 with appropriate handling and storage information.  
 
 
Figure 6 Schematic representation of Cellartis iPS cell to hepatocyte differentiation system (Takara Bio Europe 
AB, 2015) hiPSCs were grown in Cellartis DEF-CS Culture System (Takara Bio). Adapted to this specific media, hiPS 
cells were differentiated to definitive endoderm and then to hepatocytes.  
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Table 3 Suggested schedule for differentiation of hFmiPS1 cells to hepatocytes via definitive endoderm(Takara 
Bio Europe AB, 2015) hFmiPS1 (Korean National Institute of Health) cell line was transferred to DEF-CS Culture 
System, adapted, and expanded to be ready for differentiation into Definitive Endoderm (indicated here as day zero). 
After seven days of endoderm differentiation, the definitive endoderm cells are passaged and the differentiation process 
to hepatocyte continues.   
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Table 4 Storage and handling information of reagents necessary for hepatocyte differentiation 
Reagents 
Storage and Thawing 
Temperature 
-20°C 2 - 8°C RT 37°C 
DEF-CS Culture System  
(Takara Bio, Kusatsu, Japan) 
    
DEF-CS Basal Medium      
DEF-CS COAT-1     
GF-1, GF-2, GF-3 (Original Vial)     
GF-1, GF-2, GF-3  
(After Thawing + Aliquot) 
    
Definitive Endoderm (DE) Differentiation Kit 
(Takara Bio, Kusatsu, Japan) 
    
Original Vial     
During Thawing     
Hepatocyte Differentiation Kit 
(Takara Bio, Kusatsu, Japan) 
    
Storage of All Before Thawing     
Thawing and Seeding Medium     
Thawing Progenitor Medium     
Thawing Maturation Medium Base      
Thawing Maturation Medium Supplement     
Thawing Maintenance Medium     
Thawing Hepatocyte Coating     
Additional Materials Required     
Fetal bovine serum (FBS) from Gibco®  
(Thermo Fisher Scientific, Waltham, MA) 
    
PBS Dulbecco’s with Ca2+ & Mg2+ (D-PBS +/+) 
(Thermo Fisher Scientific, Waltham, MA) 
    
PBS Dulbecco’s w/o Ca2+ & Mg2+ (D-PBS -/-)  
(Thermo Fisher Scientific, Waltham, MA) 
    
ACCUTASE™  
(STEMCELL Technologies, Vancouver, BC) 
    
 21 
Transferring iPSC to the Cellartis DEF-CS Culture System 
 Three passages were passed to adapt iPSC line, hFmiPS1 (Korean National 
Institute of Health, Seoul, Korea), to the Cellartis DEF-CS Culture system.  
Coating Cell Culture Vessels 
200 µl of Cellartis DEF-CS COAT-1 was diluted with 800 µl D-PBS (+/+) (1:5 
dilution ratio) to provide extra support during the adaptation process. Mixed solution was 
added to 6-well plate with a surface area of 9.61cm2 and placed in an incubator at 37°C ± 
1°C, 5% CO2, and >90% humidity for 20 minutes. Solution was aspirated from the plate 
just before use. For next passages, 50 µl of DEF-CS COAT-1 solution was mixed with 
950 µl of D-PBS (+/+). 
Preparing Cellartis DEF-CS Medium 
 Different medium mixture should be used for maintenance and passaging iPS 
cells. For maintenance, supplemented Cellartis DEF-CS medium were prepared by  
adding 9 µl of DEF-CS GF-1 (dilute 1:333) and 3 µl GF-2 (dilute 1:1000) to the 3mL 
Cellartis DEF-CS Basal Medium. For passaging, supplemented Cellartis DEF-CS 
medium were prepared by adding 6µL of DEF-CS GF-1 (dilute 1:333), 2 µl GF-2 (dilute 
1:1000) and 2 µl GF-3 (dilute 1:1000) to the 2mL Cellartis DEF-CS Basal Medium. 
Fresh medium was prepared on the day of intended use and warmed to 37°C before use. 
Passaging Human iPS Cell Lines 
Cells were checked under microscope and photo documented. Previous medium 
from the cell culture was aspirated and cells were washed with D-PBS (-/-). 200 µl (20 µl 
/cm2) of ACCUTASE™ was added to the cell culture and incubated for 5 minutes until 
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the cell layer was detached. Cells were resuspended in the supplemented DEF-CS 
medium. Solution was pipetted up and down several times to ensure a single cell 
suspension. Cells were counted. 2mL (0.2mL/cm2) of supplemented DEF-CS medium, 
previously prepared and warmed, was added to the newly coated 6-well plate. 
Appropriate volume of cell suspension was seeded to a new dish at a density of 5 X 104 
cells/cm2. Plate was mixed gently by tilting it backwards and forwards and placed in the 
incubator at 37°C ± 1°C, 5% CO2, and >90% humidity. 2 wells in 6-well plate were 
used. 
Changing Medium for iPS Cell Lines 
Cells were checked under microscope and photo documented. Previous medium 
was aspirated carefully using vacuum pump and newly warmed 3mL (0.3 mL/cm2) 
supplemented medium was added to the cell culture plate. Cell culture flask was placed 
in the incubator at 37°C ± 1°C, 5% CO2, and >90% humidity. 
 
Cellartis Definitive Endoderm Differentiation 
Preparation 
 Definitive Endoderm Differentiation solutions from Day 0 to Day 6 were thawed, 
aliquoted to the appropriate volume (2mL for Day 0, 1 and 2; 2.7mL for Day 3; 5mL for 
Day 4 and 6) and then refrozen on -20°C. Definitive Endoderm Differentiation Coating 
Solution was thawed and warmed to RT. Aliquoted Definitive Endoderm Differentiation 
Day 0 solution was thawed and warmed to RT. 
Coating Cell Culture Vessels 
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 1mL (0.1mL/cm2) of Definitive Endoderm Differentiation solution was added to 
the 6-well plate and spread out to ensure all the surface was covered. The plate was 
incubated at RT for 60 minutes. Definitive Endoderm Differentiation Coating solution 
was aspirated just before seeding. 3 wells in 6-well plate were prepared. 
Seeding Cells 
 Cells were checked under microscope and photo documented. Previous medium 
from the cell culture was aspirated and cells were washed with D-PBS (-/-). 200 µl (20 µl 
/cm2) of ACCUTASE™ was added to the cell culture and incubated for 5 minutes until 
the cell layer was detached. Cells were resuspended in the supplemented DEF-CS 
medium. Solution was pipetted up and down several times to ensure a single cell 
suspension. Cells were counted. Approximately 1.2 x 106 cells from 2 wells were 
transferred to a 15-mL conical centrifuge tube, which was then centrifuged for 5 minutes 
at 200 x g at RT. The supernatant was removed and cells were resuspended in 6mL 
(0.2mL/cm2) of Definitive Endoderm Differentiation Day 0 solution. 2mL of resuspended 
cells were seeded in each of the coated cell culture plate and transferred to the incubator 
at 37°C ± 1°C, 5% CO2, and >90% humidity. 
Changing Medium for Day 1 to Day 6 
 For each day of endoderm differentiation (Table 3), corresponding Definitive 
Endoderm Differentiation solution (2mL for Day 0, 1 and 2; 2.7mL for Day 3; 5mL for 
Day 4 and 6) was thawed and warmed to 37°C. Previous medium from the culture vessels 
was removed with a vacuum pump and appropriate volume (2mL for Day 0, 1 and 2; 
2.7mL for Day 3; 5mL for Day 4 and 6) of Definitive Differentiation solution was added 
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to each well. Cell culture plate was placed in the incubator at 37°C ± 1°C, 5% CO2, and 
>90% humidity. Three wells in 6-well plate were prepared. 
 
Cellartis Hepatocyte Differentiation 
Total surface area of 14cm2 will be used corresponding to 8 wells in 8-well 
chamber (each well surface area of 0.8cm2) and 4 wells in 24-well plate (each well 
surface area of 1.9cm2).   
Coating Cell Culture Vessels 
0.15ml/cm2 of Hepatocytes Coating solution was thawed at RT and added to 4 
wells in 24-well plate, and 8 wells in 8-well chamber ensuring that the entire surface was 
covered. It was incubated at 37°C for 30 minutes. Excess Hepatocyte Coating solution 
was removed from the 24-well plate just before seeding.  
Passaging Definitive Endoderm Cells (Day 7) 
 Hepatocyte Thawing and Seeding Medium was thawed and warmed to 37°C. 
ACCUTASE™ and D-PBS (-/-) were warmed to 37°C. 10% FBS in D-PBS (-/-) was 
prepared and warmed to RT. Previous medium from Day 6 Definitive Endoderm cell was 
removed with a vacuum pump. The 6-well dish cell culture vessels were washed with 
1mL of warm D-PBS (-/-) and removed with a vacuum pump. 1mL of warm 
ACCUTASE™ was added to the cell culture vessel and incubated at 37°C ± 1°C, 5% CO2 
for 3 minutes. The cell suspension from three wells in 6-well dish was transferred to a 15 
mL conical centrifuge tube. The cell culture vessels were rinsed with 1mL of 10% FBS 
and transferred to the same 15mL conical centrifuge tube to achieve 1:1 dilution of the 
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cell suspension. Cells were counted and an appropriate volume of the cell suspension 
corresponding to 2 x 106 cells (1.2-1.3 x 105 cells/cm2) were transferred to a new 15mL 
conical centrifuge tube. The cell suspension was centrifuged at 300 x g for 5 minutes at 
RT. Supernatant was removed and the cell pellet was resuspended in 7 mL of Hepatocyte 
Thawing and Seeding Medium (0.5 mL/cm2). Cells were placed in the incubator at 37°C 
± 1°C, 5% CO2, and >90% humidity. 
Changing Medium (Hepatocyte Progenitor, Maturation & Maintenance) 
 Cells were checked under microscope and photo documented. Previous medium 
was aspirated carefully using 1 mL pipet. On day 9 and 11 (Table 3), 0.5 mL/cm2 of 
Hepatocyte Progenitor Medium was added to 24-well plate and 8-well chamber 
corresponding to their surface areas. On day 14, Hepatocyte Maturation Medium Base 
was thawed and warmed to RT and 1.3 mL of Maturation Medium Supplement was 
added to make the complete Hepatocyte Maturation Medium. Previous medium was 
aspirated carefully using 1 mL pipet and 0.5 mL/cm2 of RT Hepatocyte Maturation 
Medium was added to the cell culture plate. Cells were placed in the incubator at 37°C ± 
1°C, 5% CO2, and >90% humidity. The remaining Hepatocyte Maturation Medium was 
stored at 4°C for medium change on Day 16. Repeat Day 14 process for Day 16 (Table 
3). From day 18 onwards (Table 3), the Hepatocyte Maintenance Medium was used for 
medium changes. Hepatocyte Maintenance Medium was thawed at RT. Previous medium 
was aspirated carefully using 1 mL pipet and 0.5 mL/cm2 of RT Hepatocyte Maintenance 
Medium was added to the cell culture plate. Cells were placed in the incubator at 37°C ± 
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1°C, 5% CO2, and >90% humidity. Before starting any assays, medium was changed for 
the optimal results.  
 
RNA Isolation and Polymerase Chain Reaction (PCR) 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany) from 
which 1 µg of purified RNA was reverse-transcribed with Reverse Transcription System 
(Takara, Kyoto, Japan) according to the manufacturer’s instructions. Amplification was 
carried out by denaturation at 94°C for 2 mins, followed by 30 cycles of denaturation at 
94°C for 45 secs, annealing at specific annealing temperatures for each primer for 45 sec, 
and finally elongation at 72°C for 1 min. Five hepatic markers were used to validate 
differentiation into hepatocytes: AFP, TTR, HNF-4α, ALB and HNF-1α.  Stem cell 
markers, SOX2 and Oct-4 were used to make sure iPS cells were fully differentiated into 
hepatocytes. Sequences of primers used for RT-PCR are listed in Table 5.  
Table 5 Forward and reverse primer sequences for seven marker genes and GAPDH. 
Marker 
Genes 
Product 
Size (bp) 
Tm 
(°C) 
Forward Primer Reverse Primer 
SOX2 466 59.95 AGAACCCCAAGATGC
ACAAC 
ATGTAGGTCTGCGAG
CTGGT 
Oct-4 272 60.05 AGTGAGAGGCAACCT
GGAGA 
GTGAAGTGAGGGCTC
CCATA 
AFP 402 56.8 TTGACTGCAATTGAG
AAACC 
TGTTTGGAAGCATTC
AACTG 
TTR 412 59.25 CCTTGCTGGACTGGT
ATTTGTG 
TTCCTTGGGATTGGT
GACGACAG 
HNF-4α 466 57.15 AGTACATCCCAGCTT
TCTGC 
ATGAACTGGATCTGC
TCGAT 
ALB 497 57 TGAGACCAGAGGTTG
ATGTG 
TTTTTCACAGCATTCC
TTCA 
HNF-1α 497 57 TGAGACCAGAGGTTG
ATGTG 
TTTTTCACAGCATTCC
TTCA 
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GAPDH 415 60 ACCCAGAAGACTGTG
GATGG 
TGCTGTAGCCAAATT
CGTTG 
 
Immunocytochemistry Analysis 
 Cells were grown on Lab-Tek II chamber slide (Nalge Nunc Int.), rinsed three 
times in PBS and fixed in ice-cold methanol for 20 mins at RT, and rinsed again in PBS. 
The cells were incubated for overnight at 4℃ with following antibodies: HNF-4α (1:100, 
Abcam); CK-18 (1:150, Abcam); CYP3A (1:100, Abcam); Alb (1:100, Abcam). The 
cells were rinsed in PBS and incubated for 1 hr at RT with either Alexa fluor 488 goat 
anti-rabbit IgG (1:500, Thermo Fisher Scientific, Waltham, MA) and Alexa fluor 488 
donkey anti-mouse IgG (1:500, Thermo Fisher Scientific, Waltham, MA). For 
counterstaining of cell nuclei, cells were incubated with DAPI (496-diamidino-2-
phenylindole; 1 mg/ml, Sigma-Aldrich) for 10 seconds. After washing with PBS, 
coverslips were mounted on glass slides using Vectashield mounting media (Vector 
Laboratories, Burlingame, CA) and analyzed using an LSM 700 confocal microscope 
(Carl Zeiss Inc., Oberkochen, Germany). 
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RESULTS 
Safe Harbor Site for F9 Knock-In 
RNA-Seq analysis was performed to determine Fragments Per Kilobase of 
transcript per Million mapped reads (FPKM). FPKM of several genes were determined to 
establish safe harbor site for F9 knock-in using CRISPR/Cas9 system. Since the relative 
expression of a transcript is proportional to the number of cDNA fragments that originate 
from it, mean FPKM showed which gene was highly expressive in hepatocytes. Three 
genes were determined to be highly expressive, but haptoglobin gene (HP) was chosen as 
the best harbor site for the novelty of the study. This gene had mean FPKM of 7998 with 
standard deviation of 388 (Table 6). Compared with HP, F9 gene had a significantly 
lower expression, FPKM of 42.2 with standard deviation of 0.43 (Figure 7).   
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Table 6 Mean FPKM values of potential safe harbor sites for F9 knock-in.  
GeneName Chr # Description 
Mean FPKM 
(3 Samples) 
STDEV 
ALB 4 
albumin [Source:HGNC 
Symbol;Acc:399] 
13326.6 328.0553917 
FTL 19 
ferritin, light polypeptide 
[Source:HGNC 
Symbol;Acc:3999] 
10535.26667 70.14158697 
FTH1 11 
ferritin, heavy polypeptide 1 
[Source:HGNC 
Symbol;Acc:3976] 
9456.756667 364.7675068 
ACTB 7 
actin, beta [Source:HGNC 
Symbol;Acc:132] 
8371.276667 215.4150463 
HP 16 
haptoglobin [Source:HGNC 
Symbol;Acc:5141] 
7998.266667 388.356947 
APOC3 11 
apolipoprotein C-III 
[Source:HGNC 
Symbol;Acc:610] 
7112.196667 530.1616971 
SOD2 6 
superoxide dismutase 2, 
mitochondrial [Source:HGNC 
Symbol;Acc:11180] 
4310.36 111.3165364 
ORM1 9 
orosomucoid 1 [Source:HGNC 
Symbol;Acc:8498] 
4239.533333 93.51364725 
F9 X 
coagulation factor IX 
[Source:HGNC 
Symbol;Acc:3551] 
42.20366667 0.429069212 
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Figure 7 Mean FPKM of HP and APOC3 genes compared with FPKM of common disease gene HP – 
Haptoglobin, APOC3 – Apolipoprotein C-III, F9 – Coagulation Factor IX (Lacking in HB), IDUA - Iduronidase, 
Alpha-L (Lacking in Hurler’s Disease), IDS - Iduronate 2-sulfatase (Lacking in Hunter Syndrome), GLA - alpha-
galactosidase A (Lacking in Fabry Disease), GBA - Beta-glucocerebrosidase (Lacking in Gaucher Disease). HP gene is 
transcribed at a much faster rate than F9 gene. 
 
Optimizing sgRNA Targeting F9 
 In order to successfully knock-out wildtype F9 gene from iPS cells, Cas-Designer 
was used on the web to select sgRNA target site with the most efficiency of insertions 
and deletions. Most efficient RNA-guided engineered nucleases (RGENs) target site had 
an indel efficiency of 61% (Figure 8). Therefore, it was determined that this sgRNA 
could be used to effectively knock-out F9 gene using CRISPR/Cas9 system. 
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Figure 8 Screening of sgRNA targeting human F9; Table (Top) and Graph (Bottom) Using Cas-Designer, sgRNA 
hF9-Ex1-Sp1 with the corresponding target sequence was determined to have the greatest indel frequency, insertion at 
56.7% and deletion at 4.2%, amounting to total indel frequency of 61%.   
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Targeted Deep Sequencing  
 Targeted deep sequencing was performed on the genomic DNA of two samples, 
control iPSC and F9-knockout iPSC. Control iPSC had 0% indel frequency. iPSC treated 
with CRISPR/Cas9 system with sgRNA specifically targeting F9 allele had indel 
frequency of 12.3% (Figure 9).  
 
Figure 9 Targeted deep sequencing to show indel frequency of control and CRISPR/Cas9-treated iPS cells; 
Table (Top), Graph (Bottom). Targeted deep sequencing was performed on the genomic DNA of two samples, 
control iPSC and F9-knockout iPSC. Indel frequency was 0% for control iPSC and 12.3% for F9-knockout iPSC. 
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iPSC to Hepatocyte Differentiation Via Definitive Endoderm 
iPSC was adapted to DEF-CS Culture System. iPSCs previously cultured in 
aggregated passing methods were adapted into the system that utilizes single-cell 
passaging. Since individual iPSCs that grow in colony can’t receive growth factors 
homogeneously, they were spread out into monolayer so they can differentiate to 
hepatocytes at a similar rate. As iPSCs differentiated into hepatocytes, their typical 
undifferentiated stem cell morphology disappeared (Figure 10). 
  
3
4
 
  
Figure 10 Cellular morphology showing iPS cells to hepatocyte differentiation. Cellular morphology was documented throughout the differentiation of iPSCs to 
hepatocytes. 
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Hepatocyte Validation Using Specific Markers 
 iPSCs-derived hepatocytes were validated of their differentiation through 
immunocytochemistry using specific hepatic markers. Two hepatocyte progenitor 
markers were used: HNF-4α and CK-18. Two mature hepatic markers were used: CYP3A 
and Alb. These markers were also used to stain primary hepatocyte cell line, HepG2. For 
counterstaining of cell nuclei, DAPI was used. Results are shown on the Figure 11. 
 Gene expression was analyzed with PCR technique and results shown in gel 
electrophoresis. Several genes from iPSC-derived hepatocytes were amplified after RNA 
isolation. Two stem cell markers were used: Sox2 and OCT-4. Five hepatic markers were 
used: AFP, TTR, HNF-4α, Albumin, HNF-1α. iPSC was used as a negative control and 
HepG-2 (primary hepatocyte cell line) was used as a positive control. Stem cell markers 
were only shown in iPSCs. Hepatic markers were shown in iPSC-derived hepatocytes 
and HepG-2 (Figure 12). 
  
3
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Figure 11 Immunocytochemistry of iPSC-derived hepatocytes using specific hepatic markers. Two hepatocyte progenitor markers were used, HNF-4α and CK-18. 
Two Mature hepatocyte markers were used CYP3A and Alb. Cellular nuclei were counterstained with DAPI and merged. Staining was performed on both iPSC-derived 
hepatocytes and HepG2 cell line as a positive control.    
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Figure ?? PCR and gel electrophoresis using hepatic markers to validate differentiation of iPSC to hepatocytes. 
iPSC was used as a negative control and HepG-2 (primary hepatocyte cell line) was used as a positive control. Two 
stem cell markers were used: Sox2 and OCT-4. Five hepatic markers were used: AFP, TTR, HNF-4α, Alb, HNF-1α .  
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DISCUSSION 
 
HP as Potent Liver Safe Harbor Gene 
 In order to develop a successful method of permanent gene therapy for HB 
patients, a liver safe harbor site was examined in order that even a small frequency of 
successful knock-in (0.01-0.05%) to this site using CRISPR/Cas9 system can induce an 
expression of FIX to a significant level of therapeutic effects. Many potential highly 
expressed loci in hepatocyte were examined. Three sites were determined to be highly 
expressive in hepatocytes, but haptoglobin gene (HP) was selected for the novelty of the 
study; Alb gene had been used as the target site for many previous gene knock-in studies. 
Compared to FPKM value of F9, FPKM value of HP was significantly larger to about 
190-fold. Since the relative expression of a transcript is proportional to the number of 
cDNA fragments that originate from it, HP gene could be manipulated as a target site in 
order to knock-in F9 allele with significant therapeutic results. Since F9 knock-in was not 
performed yet, it is hard to determine whether this site can truly enhance the expression 
level of FIX in vivo or ex vivo, especially since the knock-in efficiency using 
CRISPR/Cas9 was not determined yet. However, by knocking in F9 into highly 
expressed liver site, it is likely to compensate for the lower knock-in efficiency of 
CRISPR/Cas9 system.  
 
HB Model iPSC Lacking F9 Gene 
 Currently, there are no iPSCs modeling HB disease in any of the stem cell banks. 
Therefore, the purpose of this study was to generate the proper model of human HB 
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hepatocytes using CRISPR/Cas9-mediated genome editing on healthy human iPSCs. First 
step was to design an sgRNA that can effectively guide Cas9 protein to F9 site and cause 
an indel mutation, resulting in knock-out of the gene. Using Cas-Designer, sgRNA was 
generated that can cause an indel at a frequency of 61% (Figure 8). Normal iPSCs were 
treated with this sgRNA and Cas9 protein to generate F9 knock-out iPSCs. Targeted deep 
sequencing revealed an indel frequency of 12.3% (Figure 9). Since indel frequency was 
somewhat less than expected, it is necessary to optimize knock-out conditions in order to 
increase indel frequency. We were able to isolate several individual iPSCs treated with 
CRISPR/Cas9 system and grow them into a colony to screen for the one that contains 
purely F9 knock-out cells (Figure 13). Future direction should be aimed at sequencing 
such colony to verify F9 knock-out and then proceeding to differentiation of that colony 
into hepatocytes to generate a proper hepatocyte model for HB disease. 
 
Figure 13 Single cell cloning of F9 knock-out iPSCs. Several colonies were grown to screen for the 
colony that had successful indel mutation at F9 gene. From left to right, a single cell was isolated and then 
grown over time. 
 
 
iPSC to Hepatocyte Differentiation Via Definitive Endoderm  
Normal iPSCs, hFmiPS1, were successfully differentiated to hepatocytes via 
several stages, including definitive endoderm, ventral foregut, hepatoblast, fetal-like 
hepatocyte and then mature hepatocytes. Hepatocytes derived from iPSCs were validated 
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hepatocytes using CRISPR/Cas9-medi ted g nom  editing on healthy human iPSCs. First
step was to design an sgRNA that can effectively guide Cas9 protein to F9 site and cause 
an indel mutation, resulting in knock-out of the gene. Using Cas-Designer, sgRNA was 
generated that can cause an indel at a frequency of 61% (Figure 8). Normal iPSCs were 
treated with this sgRNA and Cas9 protein to generate F9 knock-out iPSCs. Targeted deep 
sequencing revealed an indel frequency of 12.3% (Figure 9). Since indel frequency was 
somewhat less than expected, it is necessary to optimize knock-out conditions in order to 
increase indel frequency. We were able to isolate several individual iPSCs treated with 
CRISPR/Cas9 system and grow them into a colony to screen for the one that contains 
purely F9 knock-out cells (Figure 13). Future direction should be aimed at sequencing 
such colony to verify F9 knock-out and then proceeding to differentiation of that colony 
into hepatocytes to generate a proper hepatocyte model for HB disease.      
 
Figure 93 Single cell cloning of F9 knock-out iPSCs. Several colonies were grown to screen for the colony that had 
successful indel mutation at F9 gene. From left to right, a single cell was isolated and then grown over time.  
 
iPSC to Hepatocyte Differentiation Via Definitive Endoderm 
 Normal iPSCs, hFmiPS1, were successfully differentiated to hepatocytes via 
several stages, including definitive endoderm, ventral foregut, hepatoblast, fetal-like 
hepatocyte and then mature hepatocytes. Hepatocytes derived from iPSCs were validated 
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of their differentiation by immunocytochemistry staining and PCR analysis. Two 
hepatocyte progenitor markers, HNF-4α and CK-18, were used on day 18 to make sure 
differentiation procedure was on the right track. Two mature hepatocyte markers, CYP3A 
and Alb, were used on day 23 to validate complete differentiation into hepatocytes. Using 
primary hepatocyte cell line, HepG2, as control, immunocytochemistry of iPSC-derived 
hepatocytes was compared. Staining results confirmed that differentiation was successful. 
All four markers were shown on the cell nuclei counterstained with DAPI (Figure 12).  
 PCR analysis was done to make sure stem cell markers were absent from iPSC-
derived hepatocytes and also to confirm complete hepatocyte markers. Since these 
hepatocytes are being differentiated to be implanted into HB patient’ liver, it was 
imperative that no iPSCs were remaining because they could develop into teratoma and 
cause a greater risk. Therefore, two stem cell markers, Sox2 and OCT-4, were used to 
check for stemness. Sox2 expression was completely absent from iPSC-derived 
hepatocytes but OCT-4 was faintly present, which raised up concerns. However, since 
HepG2, a primary hepatocyte cell line, also showed a small OCT-4 expression, it was 
concluded that fully differentiated cells also contained some expression of OCT-4. Five 
hepatic gene markers, AFP, TTR, HNF-4α, Alb, HNF-1α, were chosen to validate hepatic 
differentiation during certain stages (Figure 15). Expressions of these markers in iPSC-
derived hepatocytes were compared with those from HepG-2. All these markers were 
well expressed and confirmed full differentiation into hepatocytes (Figure 13).    
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Figure 14 Hepatocyte differentiation: stages and gene expressions iPSCs were differentiated into hepatocytes via 
several stages diagrammed above.  
 
Limitations of the Study: 
 FIX expression is necessary to establish therapeutic results. For that reason, the 
experiment design included a step to knock-in F9 allele into liver safe harbor site with 
greater gene expression. However, since knock-in efficiency, which results from HDR, is 
expected to be much less than knock-out efficiency from NHEJ, it is imperative to 
optimize knock-in protocol to benefit from gene editing therapy. Without having 
significant knock-in efficiency, it will be difficult to benefit from liver safe harbor site.  
 Although sgRNA with the expected indel frequency of 61% was used, actual 
indel efficiency was merely 12% from targeted dep sequencing analysis. Such difference 
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merits a further optimization of knock-out protocol in order to increase knock-out 
efficiency. Ten single cells treated with CRISPR/Cas9 were collected and grown into 
colonies. After these colonies are grown to certain level, targeted deep sequencing is 
necessary to see which colonies have successfully gone through F9 knock-out.  
 
Future Studies and Conclusion: 
Without understanding the entire outline of the project, it is hard to grasp the 
importance of this specific study. Since this thesis only covered a portion of the project, 
as outlined in Figure 4, without proceeding with the acquired results and performing 
future studies, no therapeutic results can be established just yet. HB disease specific iPSC 
model was generated and differentiation protocol of iPSCs to hepatocytes was established 
and successfully performed. Future studies will use this disease specific iPSCs to knock-
in F9 allele back into liver safe harbor site, HP gene (Figure 16). After confirming FIX 
expression and checking against any off-target insertions, these iPSCs will be 
differentiated into hepatocytes using the same differentiation protocol. Seoul National 
University will develop transgenic knock-out mice that model HB disease using 
CRISPR/Cas9. Hepatocytes derived from genetically modified iPSCs will be injected 
into the liver of these transgenic mice to check for any therapeutic effects. In vivo study 
will be performed using AAV vector and CRISPR/Cas9, directly manipulating genes in 
the hepatocytes of transgenic mice. The project will examine which method is better for 
final therapeutic evaluations (ex vivo or in vivo) and develop most efficient method of 
permanent gene therapy for HB patients. With HB as a model for many hereditary 
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diseases to overcome, this gene therapy design using liver safe harbor site will be 
replicated for other genetic diseases including Gaucher disease, Fabry disease, Hunter’s 
diseases and others to establish long-term therapeutic effects (Figure 16).   
 
 
Figure 15 Safe harbor site targeting liver-biofactory design With HB as the model genetic disease to overcome, 
liver safe harbor site using CRISPR/Cas9 will be used for many other hereditary diseases to establish long-term 
therapeutic effects (Toolgen Inc, Seoul, Korea).  
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